ST
NBIX icon

Spot Trading’s Neurocrine Biosciences NBIX Stock Holding History

Spot Trading’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,000
Closed -$57K – 3779
2015
Q4 		$57K Sell
1,000
-300
-23% -$15.2K ﹤0.01% 3005
2015
Q3 		$52K Buy
+1,300
New +$62.8K ﹤0.01% 3274
2014
Q3 		– Sell
-57,100
Closed -$847K – 4585
2014
Q2 		$847K Buy
57,100
+17,100
+43% +$241K ﹤0.01% 2266
2014
Q1 		$644K Buy
+40,000
New +$684K ﹤0.01% 2335

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Spot Trading's NBIX Position: Q1 2016 in Review

Spot Trading sold out of Neurocrine Biosciences (NBIX) in Q1 2016, closing a stake of 856 shares — an estimated $48K sold.

Spot Trading first reported a position in NBIX in Q2 2014 and held it in 5 quarters. The position peaked at $363K in Q4 2014. 212 funds tracked by Wall St. Rank hold NBIX as of Q1 2016.

  • Spot Trading reported no remaining Neurocrine Biosciences position as of Q1 2016 after selling out during the quarter.
  • Spot Trading sold 856 Neurocrine Biosciences shares in Q1 2016, an estimated $48K.
  • Spot Trading first reported a position in Neurocrine Biosciences in Q2 2014 and held it in 5 quarters.
  • Spot Trading's Neurocrine Biosciences position peaked at $363K in Q4 2014.
  • 212 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2016.

Based on Spot Trading's 13F filing for Q1 2016, filed 10 May 2016.